Fig. 7
Regulation of inflammation and immunity genes, and prostate cancer driver genes in IL30 overexpressing PC cells cocultured with endothelial cells and in IL30 overexpressing tumor xenografts and clinical PC samples. A, B Fold differences of mRNAs of “prostate cancer driver” genes (A) or “inflammation & immunity” genes (B) between IL30-DU145 or IL30-PC3 cells cocultured with HUVEC versus DU145 or PC3 cocultured with HUVEC, respectively. Results obtained from control EV-transfected cells were comparable to those from wild type cells. A significant threshold of a twofold change in gene expression corresponded to p < 0.001. Experiments were performed in duplicate. C Immunohistochemical features of IL30 overexpressing PC3 and DU145 tumors showing a stronger expression of immunoregulatory genes (IL12B; a, b) and PC driver genes (SHBG; c, d) when compared to wild type tumors. Results from EV-transfected tumors were comparable to wild type tumors. Magnification: X400. D Expression of IL30 (a, b), TNFα (c, d), IL12B (e, f), SHBG (g, h) and LGALS4 (i, j) in PC tissues obtained from patients bearing IL30Neg PC or IL30Pos PC. Representative images of the immunohistochemical results are shown. Magnification: X400